FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156665587> ?p ?o ?g. }

• W2156665587 abstract "The silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation occurs frequently in acute myeloid leukemia (AML). This epigenetic alteration can be reversed by 5-aza-2'-deoxcytidine (decitabine, 5-AZA-CdR). Although 5-AZA-CdR can induce complete remissions in patients with AML, most patients relapse. The effectiveness of this therapy may be limited by the inability of 5-AZA-CdR to reactivate all TSGs due to their silencing by other epigenetic mechanisms such as histone methylation or chromatin compaction. EZH2, a subunit of the polycomb repressive complex 2, catalyzes the methylation of histone H3 lysine 27 (H3K27) to H3K27me3. 3-Deazaneplanocin-A (DZNep), an inhibitor of methionine metabolism, can reactivate genes silenced by H3K27me3 by its inhibition of EZH2. In a previous report, we observed that 5-AZA-CdR, in combination with DZNep, shows synergistic antineoplastic action against AML cells. Gene silencing due to chromatin compaction is attributable to the action of histone deacetylases (HDAC). This mechanism of epigenetic gene silencing can be reversed by HDAC inhibitors such as trichostatin-A (TSA). Silent TSGs that cannot be reactivated by 5-AZA-CdR or DZNep have the potential to be reactivated by TSA. This provides a rationale for the use of HDAC inhibitors in combination with 5-AZA-CdR and DZNep to treat AML.The triple combination of 5-AZA-CdR, DZNep, and TSA induced a remarkable synergistic antineoplastic effect against human AML cells as demonstrated by an in vitro colony assay. This triple combination also showed a potent synergistic activation of several key TSGs as determined by real-time PCR. The triple combination was more effective than the combination of two agents or a single agent. Microarray analysis showed that the triple combination generated remarkable changes in global gene expression.Our data suggest that it may be possible to design a very effective therapy for AML using agents that target the reversal of the following three epigenetic lock mechanisms that silence gene expression: DNA methylation, histone methylation, and histone deacetylation. This approach merits serious consideration for clinical investigation in patients with advanced AML." @default.
• W2156665587 created "2016-06-24" @default.
• W2156665587 creator A5055530946 @default.
• W2156665587 creator A5055819358 @default.
• W2156665587 creator A5058717713 @default.
• W2156665587 creator A5087161283 @default.
• W2156665587 date "2014-10-01" @default.
• W2156665587 modified "2023-10-03" @default.
• W2156665587 title "Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation" @default.
• W2156665587 cites W1484293540 @default.
• W2156665587 cites W1486257535 @default.
• W2156665587 cites W1963919702 @default.
• W2156665587 cites W1965262464 @default.
• W2156665587 cites W1969670934 @default.
• W2156665587 cites W1981898318 @default.
• W2156665587 cites W1990763586 @default.
• W2156665587 cites W1993510744 @default.
• W2156665587 cites W1995652309 @default.
• W2156665587 cites W1998981539 @default.
• W2156665587 cites W2004380688 @default.
• W2156665587 cites W2004842295 @default.
• W2156665587 cites W2009178790 @default.
• W2156665587 cites W2021785548 @default.
• W2156665587 cites W2023359129 @default.
• W2156665587 cites W2027877663 @default.
• W2156665587 cites W2027978263 @default.
• W2156665587 cites W2029200519 @default.
• W2156665587 cites W2037548653 @default.
• W2156665587 cites W2039768402 @default.
• W2156665587 cites W2041686632 @default.
• W2156665587 cites W2042087070 @default.
• W2156665587 cites W2053421436 @default.
• W2156665587 cites W2072361605 @default.
• W2156665587 cites W2079095145 @default.
• W2156665587 cites W2081391009 @default.
• W2156665587 cites W2086990980 @default.
• W2156665587 cites W2088612988 @default.
• W2156665587 cites W2092340195 @default.
• W2156665587 cites W2092723585 @default.
• W2156665587 cites W2108552793 @default.
• W2156665587 cites W2109895173 @default.
• W2156665587 cites W2113634596 @default.
• W2156665587 cites W2113956050 @default.
• W2156665587 cites W2117612044 @default.
• W2156665587 cites W2119371810 @default.
• W2156665587 cites W2128919238 @default.
• W2156665587 cites W2149058047 @default.
• W2156665587 cites W2153183019 @default.
• W2156665587 cites W2153640125 @default.
• W2156665587 cites W2159890926 @default.
• W2156665587 cites W2160968219 @default.
• W2156665587 cites W2164052369 @default.
• W2156665587 cites W2171256063 @default.
• W2156665587 cites W2171676482 @default.
• W2156665587 cites W4253812362 @default.
• W2156665587 doi "https://doi.org/10.1186/1868-7083-6-19" @default.
• W2156665587 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4194463" @default.
• W2156665587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25313314" @default.
• W2156665587 hasPublicationYear "2014" @default.
• W2156665587 type Work @default.
• W2156665587 sameAs 2156665587 @default.
• W2156665587 citedByCount "57" @default.
• W2156665587 countsByYear W21566655872015 @default.
• W2156665587 countsByYear W21566655872016 @default.
• W2156665587 countsByYear W21566655872017 @default.
• W2156665587 countsByYear W21566655872018 @default.
• W2156665587 countsByYear W21566655872019 @default.
• W2156665587 countsByYear W21566655872020 @default.
• W2156665587 countsByYear W21566655872021 @default.
• W2156665587 countsByYear W21566655872022 @default.
• W2156665587 countsByYear W21566655872023 @default.
• W2156665587 crossrefType "journal-article" @default.
• W2156665587 hasAuthorship W2156665587A5055530946 @default.
• W2156665587 hasAuthorship W2156665587A5055819358 @default.
• W2156665587 hasAuthorship W2156665587A5058717713 @default.
• W2156665587 hasAuthorship W2156665587A5087161283 @default.
• W2156665587 hasBestOaLocation W21566655871 @default.
• W2156665587 hasConcept C104317684 @default.
• W2156665587 hasConcept C119056186 @default.
• W2156665587 hasConcept C119157956 @default.
• W2156665587 hasConcept C150194340 @default.
• W2156665587 hasConcept C190727270 @default.
• W2156665587 hasConcept C2776262904 @default.
• W2156665587 hasConcept C2776915012 @default.
• W2156665587 hasConcept C2777865847 @default.
• W2156665587 hasConcept C2778305200 @default.
• W2156665587 hasConcept C2780235182 @default.
• W2156665587 hasConcept C2780737395 @default.
• W2156665587 hasConcept C41091548 @default.
• W2156665587 hasConcept C50171091 @default.
• W2156665587 hasConcept C502942594 @default.
• W2156665587 hasConcept C54355233 @default.
• W2156665587 hasConcept C64927066 @default.
• W2156665587 hasConcept C83640560 @default.
• W2156665587 hasConcept C86803240 @default.
• W2156665587 hasConceptScore W2156665587C104317684 @default.
• W2156665587 hasConceptScore W2156665587C119056186 @default.
• W2156665587 hasConceptScore W2156665587C119157956 @default.
• W2156665587 hasConceptScore W2156665587C150194340 @default.
• W2156665587 hasConceptScore W2156665587C190727270 @default.

• next